Cyclacel Pharmaceuticals IncNASDAQ:CYCCNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.7000
- TODAY'S CHANGE (%)0.0200 (1.1905%)
- Bid / Lots1.6800/ 1
- Ask / Lots1.7000/ 1
- Open / Previous Close1.6800 / 1.6800
- Day Range
- 52 Week Range
- Volume76,107
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CYCC |
|---|---|---|
| 09:32 ET | 245 | 1.68 |
| 09:45 ET | 652 | 1.7099 |
| 09:50 ET | 288 | 1.6824 |
| 09:52 ET | 1000 | 1.7054 |
| 10:15 ET | 193 | 1.7 |
| 10:21 ET | 3049 | 1.651 |
| 10:24 ET | 100 | 1.69 |
| 10:26 ET | 2599 | 1.6587 |
| 11:47 ET | 200 | 1.65 |
| 11:51 ET | 200 | 1.666 |
| 11:58 ET | 978 | 1.6527 |
| 12:16 ET | 2149 | 1.6492 |
| 12:41 ET | 3120 | 1.6464 |
| 12:52 ET | 173 | 1.6475 |
| 12:59 ET | 100 | 1.63 |
| 01:03 ET | 750 | 1.635 |
| 01:12 ET | 850 | 1.6225 |
| 01:17 ET | 1251 | 1.62 |
| 01:19 ET | 100 | 1.6454 |
| 02:11 ET | 100 | 1.6262 |
| 02:26 ET | 200 | 1.6362 |
| 02:27 ET | 200 | 1.6398 |
| 02:40 ET | 100 | 1.625 |
| 02:42 ET | 300 | 1.62 |
| 02:58 ET | 137 | 1.64 |
| 03:00 ET | 6838 | 1.7 |
| 03:02 ET | 450 | 1.6919 |
| 03:03 ET | 200 | 1.69 |
| 03:05 ET | 24478 | 1.7399 |
| 03:14 ET | 3175 | 1.715 |
| 03:16 ET | 100 | 1.7399 |
| 03:21 ET | 200 | 1.7399 |
| 03:23 ET | 9938 | 1.7399 |
| 03:25 ET | 900 | 1.68 |
| 03:27 ET | 200 | 1.68 |
| 03:30 ET | 200 | 1.7385 |
| 03:32 ET | 584 | 1.668 |
| 03:34 ET | 411 | 1.714 |
| 03:36 ET | 422 | 1.684 |
| 03:38 ET | 571 | 1.69 |
| 03:39 ET | 100 | 1.66 |
| 03:41 ET | 400 | 1.69 |
| 03:54 ET | 100 | 1.69 |
| 03:56 ET | 897 | 1.69 |
| 03:57 ET | 1000 | 1.685 |
| 03:59 ET | 755 | 1.7 |
Jun 26, 2024
DJ Cyclacel Pharma Shares Rise 11% After European Patent Allowance Notice for Plogosertib, from 10:42AM ET on Wednesday Jun 26, 2024 by Dow Jones
10:42AM ET on Wednesday Jun 26, 2024 by Dow JonesCyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions, from 9:15AM ET on Wednesday Jun 26, 2024 by Dow Jones
9:15AM ET on Wednesday Jun 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cyclacel Pharmaceuticals Inc | 2.5M | -0.1x | --- |
Lipella Pharmaceuticals Inc | 3.0M | -0.5x | --- |
Aditxt Inc | 2.8M | 0.0x | --- |
Regen BioPharma Inc | 1.9M | -1.5x | --- |
Altamira Therapeutics Ltd | 2.6M | 0.0x | --- |
CNBX Pharmaceuticals Inc | 217.8K | -0.2x | --- |
Company Information
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
Contact Information
- Headquarters
- 200 Connell Dr Ste 1500BERKELEY HEIGHTS, NJ, United States 07922-2811
- Phone
- 908-517-7330
- Fax
- 866-271-3466
Executives
- Independent Chairman of the Board
- Samuel Barker
- President, Chief Executive Officer, Director
- Spiro Rombotis
- Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
- Paul Mcbarron
- Interim Chief Medical Officer, Director
- Brian Schwartz
- Independent Director
- Kenneth Ferguson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5M |
|---|---|
Revenue (TTM) | $449.0K |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.58 |
EPS | $-21.99 |
Book Value | $0.57 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 5.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,008.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
